Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 3 | 0 | 2 | 0 | 0 |
Analyst Firms Making Recommendations1
- Maxim Group
- Canaccord Genuity
- Raymond James
- HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Galmed Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/24/2023 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | 905.03% | Maxim Group | Jason McCarthy | → $4 | Upgrade | Hold → Buy | Get Alert |
| 08/08/2022 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 08/08/2022 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | 151.26% | Canaccord Genuity | Edward Nash | $75 → $15 | Downgrade | Buy → Hold | Get Alert |
| 05/18/2022 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | — | Raymond James | Steven Seedhouse | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/03/2022 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | — | HC Wainwright & Co. | Ed Arce | — | Downgrade | Buy → Neutral | Get Alert |
| 05/03/2022 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | 1156.28% | Raymond James | Steven Seedhouse | $210 → $75 | Maintains | Outperform | Get Alert |
| 05/17/2021 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | 5176.38% | Canaccord Genuity | — | — | Maintains | Buy | Get Alert |
| 03/19/2021 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | 6181.41% | HC Wainwright & Co. | Ed Arce | — | Maintains | Buy | Get Alert |
| 01/08/2021 | GLMD | Buy Now | Galmed Pharmaceuticals | $0.40 | 4171.36% | Raymond James | — | — | Maintains | Outperform | Get Alert |
What is the target price for Galmed Pharmaceuticals (GLMD)?
The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Maxim Group on July 24, 2023. The analyst firm set a price target for $4.00 expecting GLMD to rise to within 12 months (a possible 905.03% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Galmed Pharmaceuticals (GLMD)?
The latest analyst rating for Galmed Pharmaceuticals (NASDAQ: GLMD) was provided by Maxim Group, and Galmed Pharmaceuticals upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Galmed Pharmaceuticals (GLMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
Is the Analyst Rating Galmed Pharmaceuticals (GLMD) correct?
While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a upgraded with a price target of $0.00 to $4.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $0.40, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.